Vivimed Labs (NSE:VIVIMEDLAB) LT-Debt-to-Total-Asset: 0.00 (As of Dec. 2025)

What is Vivimed Labs LT-Debt-to-Total-Asset?

Vivimed Labs NSE:VIVIMEDLAB -3.17% 38 LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus rates NSE:VIVIMEDLAB with a GF Score™ of 38/100 and a GF Value™ of ₹2.56 (Significantly Overvalued). The stock has 7 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Vivimed Labs's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.00.

Vivimed Labs's long-term debt to total assets ratio stayed the same from Dec. 2024 (0.00) to Dec. 2025 (0.00).

Vivimed Labs (NSE:VIVIMEDLAB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Vivimed Labs LT-Debt-to-Total-Asset Related Terms

Vivimed Labs LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Vivimed Labs's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivimed Labs LT-Debt-to-Total-Asset Chart

Vivimed Labs Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.06

0.07

Vivimed Labs Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.00	0.07	0.00	0.07	0.00

38GF Score

Vivimed Labs Ltd NSE:VIVIMEDLAB

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Vivimed Labs LT-Debt-to-Total-Asset Calculation

Vivimed Labs's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2025 is calculated as

LT Debt to Total Assets (A: Mar. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2025 )	/	Total Assets (A: Mar. 2025 )
	=	636.15	/	9208.34
	=	0.07

Vivimed Labs's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	0	/	0
	=

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

Vivimed Labs (NSE:VIVIMEDLAB) has a LT-Debt-to-Total-Asset of 0.00 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Vivimed Labs and its competitors.

Is Vivimed Labs' LT-Debt-to-Total-Asset too high?

Vivimed Labs' current LT-Debt-to-Total-Asset is 0.00. Overall, Vivimed Labs has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Vivimed Labs' LT-Debt-to-Total-Asset compare to ZTS and UTHR?

Vivimed Labs' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Vivimed Labs and its competitors. Vivimed Labs's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Vivimed Labs stock overvalued right now?

Based on GuruFocus' analysis, Vivimed Labs (NSE:VIVIMEDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.56, compared to a current price of ₹5.80 — trading 126.6% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Vivimed Labs' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Vivimed Labs (NSE:VIVIMEDLAB), the current LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued. The current stock price of ₹5.80 is trading 126.6% above its estimated GF Value™ of ₹2.56. GuruFocus considers Vivimed Labs to be Significantly Overvalued.

Key valuation signals for NSE:VIVIMEDLAB:

LT-Debt-to-Total-Asset: 0.00
GF Value™: ₹2.56 vs. price of ₹5.80 (126.6% above fair value)
GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vivimed Labs Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies BOM:543963 BOM:532637 BOM:524711 BOM:540694 BOM:524703 BOM:524516 BOM:524322 BOM:524396 BOM:540702 BOM:531592 XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges 532660:India

Address Green Lands, Beside The Plaza Hotel, D.No. 6-3-866/1/G1, 3rd & 4th Floor, GMR Towers, Begumpet, Hyderabad, TG, IND, 500016

Website https://www.vivimedlabs.com

Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.

38GF Score

Get the complete analysis for NSE:VIVIMEDLAB

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5.80

Price

₹2.56

GF Value

View NSE:VIVIMEDLAB Analysis

See LT-Debt-to-Total-Asset data for all stocks →